Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + cetuximab + irinotecan
- Development stage
- Phase 2
- Lead developer
- BeiGene
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a combination regimen of three drugs—tislelizumab (a humanized IgG4 anti-PD-1 monoclonal antibody), cetuximab (a chimeric IgG1 anti-EGFR monoclonal antibody), and irinotecan (a topoisomerase I inhibitor small molecule chemotherapeutic). The combination is being investigated for the treatment of refractory or recurrent RAS wild-type metastatic colorectal cancer that has failed at least two prior lines of therapy. Tislelizumab blocks the PD-1/PD-L1 immune checkpoint pathway to enhance antitumor immunity. Cetuximab inhibits EGFR signaling to block tumor cell proliferation and may also promote immune-mediated cytotoxicity. Irinotecan inhibits DNA replication by targeting topoisomerase I. Preclinical and clinical studies suggest that combining EGFR inhibition with chemotherapy can sensitize tumors to immunotherapy in microsatellite stable colorectal cancer[1][2][7].
- Other names
- Tislelizumab Combined With Cetuximab and IrinotecanTislelizumab Plus Cetuximab and Irinotecan
02
Targets
TOP1 (DNA Topoisomerase I)EGFR (Epidermal growth factor receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on tislelizumab + cetuximab + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + cetuximab + irinotecan.